Trial Profile

Study of NMS-03305293, a Non-Trapping PARP1-Specific PARP Inhibitor in Relapsed Small Cell Lung Cancer

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 21 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NMS 293 (Primary) ; Temozolomide (Primary)
Indications Small cell lung cancer
Focus Adverse reactions
Sponsors Nerviano Medical Sciences

Most Recent Events

17 Apr 2025 Status changed from planning to not yet recruiting.
20 Jan 2025 New trial record
13 Jan 2025 According to a Nerviano Medical Sciences media release, company announced U.S. Food and Drug Administration (FDA) has granted IND approval to proceed with two clinical studies in the relapse setting for small cell lung cancer and BRCA wild-type ovarian cancer.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com